<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Scientifica (Cairo)</journal-id><journal-id journal-id-type="iso-abbrev">Scientifica (Cairo)</journal-id><journal-id journal-id-type="publisher-id">SCIENTIFICA</journal-id><journal-title-group><journal-title>Scientifica</journal-title></journal-title-group><issn pub-type="epub">2090-908X</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3820307</article-id><article-id pub-id-type="doi">10.1155/2013/217513</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="17783" pm="."><plain>Molecular Cochaperones: Tumor Growth and Cancer Treatment </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Calderwood</surname><given-names>Stuart K.</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1">Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA</aff><author-notes><corresp id="cor1">*Stuart K. Calderwood: <email>scalderw@bidmc.harvard.edu</email></corresp><fn fn-type="other"><p><text><SENT sid="17784" pm="."><plain>Academic Editors: M. H. Manjili and Y. Oji </fn></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>17</day><month>4</month><year>2013</year></pub-date><volume>2013</volume><elocation-id>217513</elocation-id><history><date date-type="received"><day>11</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>1</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Stuart K. Calderwood.</copyright-statement><copyright-year>2013</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="17788" pm="."><plain>Molecular chaperones play important roles in all cellular organisms by maintaining the proteome in an optimally folded state. They appear to be at a premium in cancer cells whose evolution along the malignant pathways requires the fostering of cohorts of mutant proteins that are employed to overcome tumor suppressive regulation. To function at significant rates in cells, HSPs interact with cochaperones, proteins that assist in catalyzing individual steps in molecular chaperoning as well as in posttranslational modification and intracellular localization. We review current knowledge regarding the roles of chaperones such as heat shock protein 90 (Hsp90) and Hsp70 and their cochaperones in cancer. Cochaperones are potential targets for cancer therapy in themselves and can be used to assess the likely prognosis of individual malignancies. Hsp70 cochaperones Bag1, Bag3, and Hop play significant roles in the etiology of some cancers as do Hsp90 cochaperones Aha1, p23, Cdc37, and FKBP1. </plain></SENT>
<SENT sid="17794" pm="."><plain>Others such as the J domain protein family, HspBP1, TTC4, and FKBPL appear to be associated with more benign tumor phenotypes. The key importance of cochaperones for many pathways of protein folding in cancer suggests high promise for the future development of novel pharmaceutical agents. </p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="17796" pm="."><plain>1. </plain></SENT>
<SENT sid="17797" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="17798" pm="."><plain>Chaperones/HSPs. Molecular chaperones are a diverse group of proteins involved in the maintenance of other “client” proteins in folded and active conformations in all cellular organisms [1–5]. </plain></SENT>
<SENT sid="17799" pm="."><plain>The term molecular chaperone is however generally reserved for proteins with a dedicated role in protein folding and refolding derived from the HSPA (HSP70), HSPB (small HSP), HSPD (Hsp60), HSPC (Hsp90), and HSPH (large HSP) gene families originally discovered as heat shock protein (HSP) genes [2, 6]. </plain></SENT>
<SENT sid="17800" pm="."><plain>Products of these genes direct the folding of much of the proteome, resulting in the formation of proteins or protein complexes capable of metabolic functions in the cell. A subset of these proteins is also expressed at high levels in cells after proteotoxic stresses such as exposure to heat shock, heavy metals, alcohols and sodium arsenite [7–10]. </plain></SENT>
<SENT sid="17802" pm="."><plain>Hence, they came to be known as heat shock proteins [7, 10]. </plain></SENT>
<SENT sid="17803" pm="."><plain>Proteotoxic stresses lead to abundant levels of unfolded, aggregated, and ubiquibinated proteins, and cells respond to such an insult by abundant synthesis of HSPs capable of resolving these perturbations to the proteome [11]. </plain></SENT>
<SENT sid="17804" pm="."><plain>These proteins are known to increase cell survival after stress both through direct chaperoning of malfolded proteins as well as inhibition of programmed cell death [12–14]. </plain></SENT>
<SENT sid="17805" pm="."><plain>Altered demand for molecular chaperones is also associated with human diseases. For instance, in age-related degenerative diseases, aggregation-prone proteins accumulate and appear to exhaust the capacity of the molecular chaperone system [15–17]. </plain></SENT>
<SENT sid="17807" pm="."><plain>Of more relevance for the current review, accumulation of mutated and overexpressed oncoproteins in cancer also leads to a demand for molecular chaperones and elevated levels of HSPs is characterize many malignancies [18–20]. </plain></SENT>
<SENT sid="17808" pm="."><plain>This dependence on molecular chaperones appears to be a soft spot in the armor of the cancer cells and has led to the development of drugs aimed at depleting molecular chaperones and degrading the cancer proteome, leading to loss of viability of the tumors [21, 22]. </plain></SENT>
<SENT sid="17809" pm="."><plain>In addition to their role in chaperoning the cancer cell proteome, HSPs are essential for evasion of a number of pathways of cell inactivation. For instance Hsp70 is involved in the inhibition of both caspase dependent apoptosis and senescence, key pathways in tumor suppression [14, 23–25]. </plain></SENT>
<SENT sid="17811" pm="."><plain>The mechanisms which underlie the elevated expression of molecular chaperones of the HSPA and HSPD families in cancer are currently unclear but may involve the dysregulation of transcription factor HSF1 first shown to couple stress to HSP transcription [8, 26]. </plain></SENT>
<SENT sid="17812" pm="."><plain>HSF1 is elevated and becomes activated in a wide range of cancers, its expression is coupled to the severity of disease, and it has been shown to be coupled to upstream signaling pathways in the malignant cell [27–31]. <p><text><SENT sid="17813" pm="."><plain>Cochaperones. As with many cellular proteins with dynamic function, HSP molecular chaperones do not appear to work alone and require the assistance of accessory proteins, known in this case as cochaperones [1, 3, 32–35] (Table 1). </plain></SENT>
<SENT sid="17814" pm="."><plain>Three particular classes of chaperone appear of high significance in cancer and these include the HSPA, HSPB, and HSPC families [19]. </plain></SENT>
<SENT sid="17815" pm="."><plain>We will discuss here the HSPA and HSPC molecular chaperone families and the associated co-chaperones. Each HSP class appears to be regulated by an individual cohort of co-chaperones and these molecules that may be significant factors in cancer and carcinogenesis and potential targets for therapy. <p><text><SENT sid="17817" pm="."><plain>Much has been discovered regarding the molecular and biochemical properties of HSPA family members such as Hsp70 and Hsc70. </plain></SENT>
<SENT sid="17818" pm="."><plain>Hsp70 family members are described as being regulated by a bidirectional heterotrophic allosteric mechanism by a tautology between target polypeptides and adenosine nucleotides [3, 36]. </plain></SENT>
<SENT sid="17819" pm="."><plain>Thus Hsp70, family proteins contain two major functional domains including an N-terminal nucleotide binding region and a C-terminal region that can interact with the hydrophobic residues in partially unfolded proteins (client binding domain) [5, 36–39] (Figure 1). “Empty” Hsp70 contains ATP in its N-terminal domain, and in this form the C-terminal domain can interact with suitably unfolded clients [3]. </plain></SENT>
<SENT sid="17820" pm="."><plain>Binding is stabilized when the uptake of clients in the C-terminal domain triggers the ATPase activity of the N domain [3]. </plain></SENT>
<SENT sid="17821" pm="."><plain>Clients are subsequently released, usually when refolded. This mechanism has been proposed to involve at least two modes of action, including (1) through stable “holding” of the client, Hsp70 maintains the levels of free unfolded client low enough to prevent aggregation; (2) inducing local unfolding in client protein domains and thus overcoming kinetic barriers to the native folded state. In the cell these biochemical properties of Hsp70 and Co. is regulated by co-chaperones that can couple activity to cell physiology/pathology [32, 40]. <p><text><SENT sid="17824" pm="."><plain>For Hsp70, co-chaperones include a large family of J domain proteins that can bind to specific substrates and foster association of such clients with Hsp70 [40, 41]. </plain></SENT>
<SENT sid="17825" pm="."><plain>These proteins contain a J domain capable of interacting with the ATP domain of the Hsp70s and a client binding domain that can associate with unfolded proteins and transfer them to the client binding site of Hsp70, resulting in a multifold stimulation in the ATPase activity of client-bound Hsp70 [41–43]. </plain></SENT>
<SENT sid="17826" pm="."><plain>There are at least 49 members of the human J domain protein family [44–46]. </plain></SENT>
<SENT sid="17827" pm="."><plain>Following the “client holding” stage of the cycle, the next step is client release and perhaps refolding. In order for Hsp70 to release clients, ADP must dissociate from the N-terminal domain, a relatively gradual reaction that can however be strongly stimulated by nucleotide exchange factors such as BAG domain proteins [45–48]. </plain></SENT>
<SENT sid="17829" pm="."><plain>The BAG (Bcl2-associated athanogene) domain interacts with the ATPase domain of Hsp70 and stimulates ADP release permitting client efflux by allosteric regulation of the N-terminal domain [47, 48]. </plain></SENT>
<SENT sid="17830" pm="."><plain>Other nucleotide exchange factors include HspBP1 [49, 50]. </plain></SENT>
<SENT sid="17831" pm="."><plain>The cytoplasmic members of the hspa family also contain a TPR domain binding (TDB) site at the extreme C-terminus. The TPR (tetratricopeptide) domain is a protein interaction motif found in a range of proteins many of which interact with molecular chaperones Hsp70 and Hsp90 [51]. </plain></SENT>
<SENT sid="17833" pm="."><plain>In the case of Hsp70, such TPR domain proteins include the scaffold protein Hop/Sti (Hop: Hsp70/Hsp90 organizing protein) and the ubiquitin E3 ligase CHIP [52–54]. <p><text><SENT sid="17834" pm="."><plain>HSPC (Hsp90) proteins, although bearing minimal sequence conservation with the HSPA family, have some biochemical properties in common with the Hsp70 proteins [55–57]. </plain></SENT>
<SENT sid="17835" pm="."><plain>The HSPC family includes four major members, including two cytoplasmic proteins Hsp90α and Hsp90β, an ER resident member glucose-regulated protein 94 (grp94) and a mitochondrially located member TRAP1 [57–60]. </plain></SENT>
<SENT sid="17836" pm="."><plain>Hsp90α and Hsp90β are of most significance in cancer where they are expressed to very high levels and are significant targets for drug development [18, 21, 61, 62]. </plain></SENT>
<SENT sid="17837" pm="."><plain>These molecules have in common with Hsp70 the ability to bind and hydrolyze ATP and to bind and modify the conformations of clients [63]. </plain></SENT>
<SENT sid="17838" pm="."><plain>Hsp90 proteins function as dimers and the ATP binding, and hydrolysis cycles regulate dimerization and client binding as with Hsp70 [56, 64–67]. </plain></SENT>
<SENT sid="17839" pm="."><plain>The nature of the client interaction domain is not entirely clear although it is thought to bind the amino acid and middle domains on the outside of the dimer [68, 69]. </plain></SENT>
<SENT sid="17840" pm="."><plain>In addition, cytoplasmic Hsp90 proteins also contain a TPR domain binding site at the C-terminus. Hsp90 interacts with an array of co-chaperones. These include p23/Sba1, a protein with intrinsic chaperone activity that stabilizes the closed conformation of Hsp90 by inhibiting ATPase activity and thus prolongs interaction with clients such as steroid hormones [70, 71]. </plain></SENT>
<SENT sid="17843" pm="."><plain>Another key co-chaperone is p50/Cell Division Cycle 37 (Cdc37) that binds the N-terminal ATP binding domain, inhibits ATPase activity, and is of particular significance in interaction with protein kinases [72–75]. </plain></SENT>
<SENT sid="17844" pm="."><plain>While p23 and Cdc37 appear to function by stabilizing Hsp90 client interactions, another co-chaperone Sgt1 appears to function at the beginning of the cycle binding ATP-free Hsp90 and helping to recruit clients to the chaperone in an analogous way to the function of JDPs in Hsp70 [76]. </plain></SENT>
<SENT sid="17845" pm="."><plain>The other core co-chaperone is Activator of the Hsp90 ATPase (Aha1), a protein that binds Hsp90 in the middle domain and triggers ATPase activity and perhaps dissociation of clients [77, 78]. </plain></SENT>
<SENT sid="17846" pm="."><plain>In addition to this core group, a large array of TPR domain co-chaperones bind to the C-terminus TDB motif of Hsp90 and can modulate chaperoning functions in specific clients, including scaffold protein Hop, protein phosphatase PP5, immunophilins FKBP1, FKBP2, Cyp4, and TPR domain proteins TTC4, TTC5, and XAP2/AIPL1 [68]. <p><text><SENT sid="17847" pm="."><plain>The TBD motifs of Hsp70 and Hsp90 proteins are key to determining the role of both proteins in intracellular protein quality control as well as more subtle interaction with bound clients. When Hsp70 binds to the multiple TPR domain scaffold protein Hop on its specific recognition site, Hsp90 can also bind to another TPR motif in Hop [79, 80]. </plain></SENT>
<SENT sid="17849" pm="."><plain>Such coupling permits a coordinated pathway of remodeling of some clients, with initial folding of nascent proteins by Hsp70/HDJ complexes commencing on the ribosome, preceding fine tuning of client conformation by Hsp90/p23/Cdc37/immunophilin complexes and full maturation of functional polypeptides [73]. </plain></SENT>
<SENT sid="17850" pm="."><plain>Alternatively, protein quality control can be biased towards proteolysis and disposal of damaged proteins when the E3 ligase CHIP binds the TBD motifs of either Hsp70 or Hsp90 [54, 81, 82]. </plain></SENT>
<SENT sid="17851" pm="."><plain>Triage between the various arms of protein quality control involves complex regulatory decision making. For instance, formation of the Hsp70/Hop/Hsp90 complex is favored by the nucleotide exchange factor Bag1 [45]. </plain></SENT>
<SENT sid="17853" pm="."><plain>Alternatively, Bag3 favors the disposal of polyubiquitinated proteins by macroautophagy [83, 84]. </plain></SENT>
<SENT sid="17854" pm="."><plain>As mentioned above, Hsp90 can bind a range of co-chaperones through the C-terminal TBD motif and can affect changes in phosphorylation of clients by PP5 and maturation of clients such as steroid hormones by immunophilins Cyp40, FKBP1, and FKBP2 [68]. </plain></SENT>
<SENT sid="17855" pm="."><plain>Although the immunophilins are able to effect proline isomerization as a basic function, these properties do not seem essential in Hsp90 cochaperone mode [85, 86]. </plain></SENT>
<SENT sid="17856" pm="."><plain>Other mechanisms seem to be involved. TTC 5 is an interesting molecule with potentially profound roles in cell physiology. This protein contains 6 TPR motifs and binds to transcriptional co-activators, activating transcription by factors such as p53 and HSF1 [87, 88]. </plain></SENT>
<SENT sid="17859" pm="."><plain>Binding to the TBD motifs on Hsp70 or Hsp90 might thus permit coupling of protein unfolding in stress or quality control to transcriptional remodeling. </sec></SecTag><sec id="sec2"><title><text><SENT sid="17860" pm="."><plain>2. </plain></SENT>
<SENT sid="17861" pm="."><plain>Hsp70 Cochaperones and Cancer </plain></SENT>
</text></title><sec id="sec2.1"><title><text><SENT sid="17862" pm="."><plain>2.1. </plain></SENT>
<SENT sid="17863" pm="."><plain>BAG Domain Proteins </plain></SENT>
</text></title><p><text><SENT sid="17864" pm="."><plain>As mentioned above, BAG domain proteins (Bag1-6) can associate with the nucleotide binding domain of Hsp70 family members, stimulate nucleotide exchange, and thus promote molecular chaperone activity (Figure 1) [3]. </plain></SENT>
<SENT sid="17865" pm="."><plain>Bag1-6 are multidomain proteins, each of which contains the Hsp70-binding BAG domain close to the C-terminus [46, 47, 89, 90]. </plain></SENT>
<SENT sid="17866" pm="."><plain>The two family members with most significance in cancer appear to be Bag1 and Bag3. </plain></SENT>
<SENT sid="17867" pm="."><plain>Bag1 also contains a UBL domain that can bind polyubiquitinated proteins and indeed has been shown to bias protein quality control towards proteolytic degradation through its ability to bind polyubiquitinated proteins [3]. </plain></SENT>
<SENT sid="17868" pm="."><plain>Bag3 contains WW and proline rich repeat sequences that appear to permit it to interact with cell signaling molecules [46]. </plain></SENT>
<SENT sid="17869" pm="."><plain>Indeed, Bag3 can interact with the molecular chaperone HspB8 and mediate macroautophagy [83]. </plain></SENT>
<SENT sid="17870" pm="."><plain>Another difference between Bag1 and Bag3 is that while Bag1 is constitutively expressed, Bag3 is conditionally inducible and indeed responds to the stress-inducible transcription factor HSF1 [91]. </plain></SENT>
<SENT sid="17871" pm="."><plain>Elevated expression of Bag1 and Bag3 in each case signals a poor prognosis for cancer bearing patients. This effect may be related to the ability of BAG/Hsp70 complexes to inhibit apoptosis [90–92]. </plain></SENT>
<SENT sid="17873" pm="."><plain>Indeed double knockdown of Bag1 and Bag3 in acute myeloid leukemia caused loss of antiapoptotic proteins Bcl2, Bcl-XL, Mcl1, and phosphor-ERK1/2 [92]. </plain></SENT>
<SENT sid="17874" pm="."><plain>The roles of Bag1 and Bag3 are somewhat complicated by their opposing role in protein quality control, with Bag1/Hsp70 favoring proteasomal degradation of clients (such as BCR-ABL oncoproteins) and Bag3 competing for binding to Hsp70 and deterring entry into the proteasome pathway [45, 46]. </plain></SENT>
<SENT sid="17875" pm="."><plain>For instance, complexing of Bag3 with Hsp70 can protect oncogenic IKK gamma from proteasomal degradation, increase flux through the NF kappa B pathway, and increase cell growth and survival [93]. </sec><sec id="sec2.2"><title><text><SENT sid="17876" pm="."><plain>2.2. </plain></SENT>
<SENT sid="17877" pm="."><plain>HspBP1 </plain></SENT>
</text></title><p><text><SENT sid="17878" pm="."><plain>Similar to the BAG domain proteins, HspBP1 is also a nucleotide exchange factor that can stimulate the ATPase cycle of Hsp70 (Figure 1). </plain></SENT>
<SENT sid="17879" pm="."><plain>Although both proteins induce nucleotide exchange, the mechanisms employed for this activity appear to involve contrasting interactions with the ATPase domain [94]. </plain></SENT>
<SENT sid="17880" pm="."><plain>In addition, HspBP1 appears to be able to oppose the proteolytic pathway of protein quality control and binding of the protein to the ATPase domain of Hsp70 inhibits the ubiquitin ligase activity of CHIP when attached to the TBP domain of Hsp70 [95]. </plain></SENT>
<SENT sid="17881" pm="."><plain>In contrast to the BAG proteins, HspBP1 appears to play a suppressive role in a number of types of cancer [96]. </plain></SENT>
<SENT sid="17882" pm="."><plain>HspBP1 levels are elevated in breast tissue and inversely related to aggressiveness [96]. </plain></SENT>
<SENT sid="17883" pm="."><plain>In addition some chemotherapeutic agents can increase cytotoxicity by inhibiting Hsp70 function [97]. </plain></SENT>
<SENT sid="17884" pm="."><plain>Hsp70 appears to inhibit a unique pathway of cell death in tumor cells involving lysosomal membrane permeabilization and activation of caspase 3 [98, 99]. </plain></SENT>
<SENT sid="17885" pm="."><plain>HspBP1 appears to oppose this Hsp70-regulated pathway [97]. </sec><sec id="sec2.3"><title><text><SENT sid="17886" pm="."><plain>2.3. </plain></SENT>
<SENT sid="17887" pm="."><plain>J Domain Proteins </plain></SENT>
</text></title><p><text><SENT sid="17888" pm="."><plain>JDPs are the most abundant family of Hsp70 co-chaperones with at least 49 members [44]. </plain></SENT>
<SENT sid="17889" pm="."><plain>The founder member of the family is the E. coli DNAJ, which along with the prokaryotic Hsp70 (DNAK) and nucleotide exchange factor (Grpe) is responsible for the bacterial Hsp70 cycle as in Figure 1 [55, 100]. </plain></SENT>
<SENT sid="17890" pm="."><plain>JDPs characteristically function by locating client proteins and ensuring their tight binding to Hsp70 [3, 44]. </plain></SENT>
<SENT sid="17891" pm="."><plain>This is assisted by the ability of JDPs to stimulate the ATPase activity of the Hsp70 chaperone and lock the client into the closed peptide binding domain [44]. </plain></SENT>
<SENT sid="17892" pm="."><plain>All JDPs contain the 70 amino acid J domain, which is essential for interaction of the protein with Hsp70. </plain></SENT>
<SENT sid="17893" pm="."><plain>There are three families of JDP, including types I, II, and III [44]. </plain></SENT>
<SENT sid="17894" pm="."><plain>JDPs tend to be either elevated to distinctly high levels or deregulated in cancer [101]. </plain></SENT>
<SENT sid="17895" pm="."><plain>However, the majority of JDP, at least in studies carried out so far, appear to be tumor suppressive in nature [44]. </plain></SENT>
<SENT sid="17896" pm="."><plain>Notable examples of tumor suppressive JDP include TID1/DNAJA3 that functions in the mitochondrial matrix as an inhibitor of carcinogenesis and mammalian relative of DnaJ (MRJ) that negatively regulates breast cancer malignancy and reduces b-catenin signaling [102–105]. </sec><sec id="sec2.4"><title><text><SENT sid="17897" pm="."><plain>2.4. </plain></SENT>
<SENT sid="17898" pm="."><plain>Hop </plain></SENT>
</text></title><p><text><SENT sid="17899" pm="."><plain>Hop, also known as STIP1, mediates Hsp70/Hsp90 interactions through their TBD domains [106] (Figure 1). </plain></SENT>
<SENT sid="17900" pm="."><plain>Only a limited amount of information is available regarding the possible involvement of Hop in cancer. However, increased levels of Hop were observed in human colon cancer, associated with increased Hsp70, Hsp90, and Hop/Hsp70/Hsp90 complexes [107]. </plain></SENT>
<SENT sid="17902" pm="."><plain>Hop expression is also increased in hepatocellular carcinoma [108]. </plain></SENT>
<SENT sid="17903" pm="."><plain>Interestingly, knockdown of Hop by RNA targeting in pancreatic cancer cells reduced the levels of proteins that have been previously isolated as Hsp90 clients in cancer such as HER2, Bcr-Abl, c-Met, and v-Src, suggesting that Hop ablation in cancer cells could be functionally similar to Hsp90 inhibition which decreases tumor growth by reducing levels of key oncoproteins [18, 22, 109]. </plain></SENT>
<SENT sid="17904" pm="."><plain>As mentioned above, Hop is a poly-TPR domain scaffold protein that couples Hsp90 to the Hsp70 folding cycle as well as to other co-chaperones, and loss of Hop may be functionally similar to deletion of the TBP domain of Hsp90, a modification that ablates chaperone function [106]. </plain></SENT>
<SENT sid="17905" pm="."><plain>In addition, Hop knockdown also led to the loss of matrix metalloproteinase 2 (MMP-2) and a decrease in cancer cell migration, also consonant with a permissive role for Hop in cancer progression [109]. </plain></SENT>
<SENT sid="17906" pm="."><plain>Hop is thus a co-chaperone for both Hsp70 and Hsp90, a coordinator of Hsp70/Hsp90 interaction, a scaffold for binding of other co-chaperones, and a potential target in cancer. </sec></sec><sec id="sec3"><title><text><SENT sid="17907" pm="."><plain>3. </plain></SENT>
<SENT sid="17908" pm="."><plain>Hsp90 Cochaperones and Cancer </plain></SENT>
</text></title><sec id="sec3.1"><title><text><SENT sid="17909" pm="."><plain>3.1. </plain></SENT>
<SENT sid="17910" pm="."><plain>P23 </plain></SENT>
</text></title><p><text><SENT sid="17911" pm="."><plain>P23 is an inhibitor of the ATPase activity of Hsp90 (Figure 2) and through this function can promote sustained interaction between hsp90 and a wide range of clients such as steroid hormone receptors and HSF1 [70, 110]. </plain></SENT>
<SENT sid="17912" pm="."><plain>Recent studies point to a role for p23 in tumor progression and cancer formation. High levels of p23 were associated with increased metastasis in breast cancer and indicated a poor prognosis including enhanced disease recurrence [111]. </plain></SENT>
<SENT sid="17914" pm="."><plain>In addition, p23 targets genes involved in drug resistance and metastasis such as PMP22, ABCC3, AGR2, Sox2, TM4SF1, and NUPR were expressed to high levels in p23 overexpressing mammary carcinoma cells [111]. </plain></SENT>
<SENT sid="17915" pm="."><plain>p23 could also be involved in the incidence of prostate cancer as a key component of the androgen receptor activity [112]. </plain></SENT>
<SENT sid="17916" pm="."><plain>Interestingly, these effects may involve both Hsp90-dependent and Hsp90-independent effects. Hsp90-independent roles for p23 have been shown previously [113]. </plain></SENT>
<SENT sid="17918" pm="."><plain>Another mechanism for increasing cancer incidence may involve inhibition of apoptosis in malignant cells. p23 is overexpressed in acute lymphoblastic leukemia (ALL) and functions as an inhibitor of chemotherapy induced apoptosis [114]. </plain></SENT>
<SENT sid="17920" pm="."><plain>These effects may be connected to loss of the microRNA species has-miR-101 in childhood ALL cases and concomitant p23 dysregulation [114]. </plain></SENT>
<SENT sid="17921" pm="."><plain>Interestingly, a novel plant product known as gedunin has been isolated that can bind p23, block its chaperoning and transcriptional activities, and lead to programmed cell death in malignant cells [115]. </sec><sec id="sec3.2"><title><text><SENT sid="17922" pm="."><plain>3.2. </plain></SENT>
<SENT sid="17923" pm="."><plain>Sgt1 </plain></SENT>
</text></title><p><text><SENT sid="17924" pm="."><plain>Sgt1 is a CHORD domain protein that acts early in the ATPase cycle of Hsp90 and may help to recruit client proteins in a similar manner to JDP for Hsp70 [116]. </plain></SENT>
<SENT sid="17925" pm="."><plain>In addition, Sgt1 can bind to Hsp70 leading to the formation of an Sgt1/Hsp90/Hsp70 chaperone complex important in the function of leucine rich repeat proteins [117]. </plain></SENT>
<SENT sid="17926" pm="."><plain>However, although Sgt1 shares sequence similarities with p23, few reports of a role for the protein in cancer are currently available. Sgt1 seems to be an important HSP co-chaperone in innate immune signaling through the intracellular NLR pathway and in kinetochore function [118, 119]. </sec><sec id="sec3.3"><title><text><SENT sid="17928" pm="."><plain>3.3. </plain></SENT>
<SENT sid="17929" pm="."><plain>P50/Cdc37 </plain></SENT>
</text></title><p><text><SENT sid="17930" pm="."><plain>Cdc37 appears to play a highly significant role in cancer and its forced expression in transgenic mice leads to prostatic hyperplasia and, when expressed in conjunction with the oncogene c-Myc, to prostate cancer [120, 121]. </plain></SENT>
<SENT sid="17931" pm="."><plain>Cdc37 is also expressed to high level in other types of malignancy such as anaplastic large cell lymphoma, acute myelocytic leukemia, hepatocellular carcinoma, and multiple myeloma [122–125]. </plain></SENT>
<SENT sid="17932" pm="."><plain>The key biochemical function of Cdc37 appears to slow down the ATPase cycle of the Hsp90 complex and extend the holding time of the client [73]. </plain></SENT>
<SENT sid="17933" pm="."><plain>Cdc37 and Hsp90 form triple complexes with many proteins, being associated with protein kinases in particular [126, 127]. </plain></SENT>
<SENT sid="17934" pm="."><plain>Such protein kinases include a long list of enzymes involved in promoting cell growth, including receptor tyrosine kinases epidermal growth factor (EGFR) and MET, nonreceptor tyrosine kinases SRC and LCK, and serine/threonine kinases RAF1, AKT1, IKK CDC2, and CDK2 (see [73, 74]). </plain></SENT>
<SENT sid="17935" pm="."><plain>Not surprisingly, reduction in Cdc37 levels by RNA interference had a profound effect in reducing tumor cell growth [128, 129]. </plain></SENT>
<SENT sid="17936" pm="."><plain>In prostate carcinoma, Cdc37 knockdown inactivated cell growth and sensitized tumors to Hsp90 inhibitors [128]. </plain></SENT>
<SENT sid="17937" pm="."><plain>It is not clear why Cdc37 is selectively carcinogenic in prostate as opposed to other tissues. One possibility is that the androgen receptor, one of the few nonkinase clients of Cdc37, is activated by elevated levels of Cdc37 [130]. </plain></SENT>
<SENT sid="17939" pm="."><plain>However, Cdc37 knockdown inhibited growth of androgen receptor negative Prostate Carcinoma (PC-3 and DU-145) as effectively as it affected androgen-requiring LnCap cells [128]. </plain></SENT>
<SENT sid="17940" pm="."><plain>In these cells, Cdc37 effectively inhibited both the ERK and Akt pathways as well as EGFR signaling [128] (J. Cheng &amp; S.K. Calderwood, in preparation). </plain></SENT>
<SENT sid="17943" pm="."><plain>Cdc37 therefore seems to be a strong molecular candidate for targeted therapy, particularly in prostate carcinoma [73]. </sec><sec id="sec3.4"><title><text><SENT sid="17944" pm="."><plain>3.4. </plain></SENT>
<SENT sid="17945" pm="."><plain>Aha1 </plain></SENT>
</text></title><p><text><SENT sid="17946" pm="."><plain>While many chaperones function to slow down the ATPase cycle of Hsp90, Aha1 triggers ATPase activity and release of client proteins from the complex [77]. </plain></SENT>
<SENT sid="17947" pm="."><plain>Despite this, Aha1 appears to be involved in increasing the activity of c-Src by Hsp90 chaperone machines and maintaining signaling activity [131]. </plain></SENT>
<SENT sid="17948" pm="."><plain>Aha1 mRNA levels are elevated in lymphoblast and testicular germ cells, although few studies have addressed levels in cancer [132]. </plain></SENT>
<SENT sid="17949" pm="."><plain>However, Aha1 concentrations appear high in promyelocytic leukemia and Daudi Burkett's lymphoma cells [132]. </plain></SENT>
<SENT sid="17950" pm="."><plain>Holmes et al. studied Aha1 protein levels in a range of human cancer cells and found markedly different levels in the different cell lines [133]. </plain></SENT>
<SENT sid="17951" pm="."><plain>Treatment with the Hsp90 inhibitory drug 17-AAG increased Ah1 levels, an effect that appeared to reflect the activation of HSF1 by the Hsp90 ablation [133]. </plain></SENT>
<SENT sid="17952" pm="."><plain>As might be predicted, reduction in Aha1 levels led to sensitization of cells to 17-AAG [133]. </sec></sec><sec id="sec4"><title><text><SENT sid="17953" pm="."><plain>4. </plain></SENT>
<SENT sid="17954" pm="."><plain>Hsp90 Interaction with TPR Domain Proteins </plain></SENT>
</text></title><p><text><SENT sid="17955" pm="."><plain>A number of proteins have been shown to bind to the TBD domains of Hsp90, including the scaffold protein Hop as mentioned above. These interactions have been intensively studied in regard to the regulation of steroid hormone receptors [63]. </plain></SENT>
<SENT sid="17957" pm="."><plain>Hsp90 and co-chaperones are thought to be continuously required to maintain proteins such as glucocorticoid receptor (GR), mineralocorticoid receptor, and progesterone receptor in stable conformations receptive to activation by their respective ligands [32, 63, 134]. </plain></SENT>
<SENT sid="17958" pm="."><plain>Receptors such as estrogen receptor and androgen receptor appear less prone to regulation by chaperone complexes [134]. </plain></SENT>
<SENT sid="17959" pm="."><plain>TPR domain proteins that interact with the C-terminal TBD of Hsp90 include protein phosphatase 5 (PP5), immunophilins FKBP1/2 and Cyp40, and TPR additional domain proteins such as TTC4, TTC5, TPR2, XAP2, and AIPL1 [134]. <p><text><SENT sid="17960" pm="."><plain>Protein Phosphatase 5 (PP5). PP5 is a serine/threonine phosphatase and is a member of the PPP phosphatase family that also includes PP1 and PPA2 [139–141]. </plain></SENT>
<SENT sid="17961" pm="."><plain>Clearly, association with a protein phosphatase has considerable potential for modulating the properties of Hsp90 complexes. Indeed, binding of PP5 to Hsp90 has potentially pleiotropic effects as the enzyme may modify the phosphorylation of Hsp90 itself as well as modulating phosphorylated sites on other co-chaperones and on its bound clients [142, 143]. </plain></SENT>
<SENT sid="17963" pm="."><plain>PP5 can dephosphorylate Hsp90 and thus positively regulate its molecular chaperone activities [142, 144]. </plain></SENT>
<SENT sid="17964" pm="."><plain>In addition, Hsp90-bound PP5 dephosphorylates the key co-chaperone Cdc37 on the residue serine 13, essential for intracellular function and thus reduces its ability to chaperone some of its many kinase clients [145]. </plain></SENT>
<SENT sid="17965" pm="."><plain>The metabolic activities of chaperoned clients may be positively or negatively regulated by Hsp90-associated PP5, depending on the nature of the phosphorylation sites involved. For instance, in lipogenesis, PP5 can simultaneously activate GR and repress Peroxisome Proliferator Activated Receptor-γ (PPAR-γ) through dephosphorylation of certain serine residues [140]. </plain></SENT>
<SENT sid="17967" pm="."><plain>In addition, Hsp90-PP5 interactions also influence cell cycle progression and DNA repair pathways through dephosphorylation of key Ser/Thr residues in DNA-dependent protein kinase and ATR [146, 147]. </plain></SENT>
<SENT sid="17968" pm="."><plain>Thus, PP5 may play a key role in regulating many aspects of chaperone complexes in cancer although it is currently not clear what the overall effect of Hsp90-associated PP5 might be. <p><text><SENT sid="17969" pm="."><plain>Immunophilins. Immunophilins are proteins that bind to immunosuppressive drugs such as cyclosporine and FK506 and have common domains with peptidyl-prolyl cis-trans isomerase (PPIase) activity [162]. </plain></SENT>
<SENT sid="17970" pm="."><plain>At least three immunophilins with TPR domains, FKBP1, FKBP2, and Cyp40, are known to bind the TBD of Hsp90 and act as co-chaperones [68]. </plain></SENT>
<SENT sid="17971" pm="."><plain>Cyp40 is present in complexes between Hsp90 and a number of steroid hormones such as GR and PR and increased transcriptional activity of the hormones when overexpressed [134, 163]. </plain></SENT>
<SENT sid="17972" pm="."><plain>Activity appears to require the TPR and PPIase domains although a role for PPIase activity in the co-chaperone properties of Cyp40 has not been demonstrated [85, 86]. </plain></SENT>
<SENT sid="17973" pm="."><plain>Cyp40 and other immunophilins may play a role in hormone-dependent malignancies such as prostate and breast cancer. Cyp40 and FKBP1 are elevated in prostate cancer compared to normal cells, positively regulate androgen dependent prostate cancer growth, and increase AR-dependent transcription [164, 165]. </plain></SENT>
<SENT sid="17975" pm="."><plain>Growth of such cancers is suppressed by cyclosporine A and FK506, the immunophilin ligands that inhibited several stages of AR signaling [164, 165]. </plain></SENT>
<SENT sid="17976" pm="."><plain>It had been shown previously that Cyp40 and FKBP2 are increased in mammary carcinoma cells by estradiol and that the antiestrogen drug ICI 182, 780 antagonized these increases [166]. <p><text><SENT sid="17977" pm="."><plain>FK506 binding proteins (FKBPs) including FKBP1 and FKBP2 are related proteins that, like Cyp40, contain a PPIase domain closely apposed to a TPR domain [135, 136]. </plain></SENT>
<SENT sid="17978" pm="."><plain>As with Cyp40, co-chaperone activity is associated with the PPIase domain but does not require PPIase activity [137]. </plain></SENT>
<SENT sid="17979" pm="."><plain>For FKBP2 at least, sequences in the PPIase domain may interact with the ligand binding domain of Hsp90 [137]. </plain></SENT>
<SENT sid="17980" pm="."><plain>FKBP2 may function by increasing nuclear transport through interaction with the motor protein dynein. Although structurally similar, these two Hsp90 co-chaperones appear to have opposing effects on nuclear receptor transcriptional activity, with the tightly binding FKBP1 inhibiting activity and the more loosely associated FKBP2 activating at least in the case of MR, GR, PR and AR [134, 137]. </plain></SENT>
<SENT sid="17982" pm="."><plain>These immunophilins may compete for binding to nuclear receptor-chaperone complexes through differential binding to the TBD of Hsp90, and for instances FKBP2 can reverse the inhibitory effects of FKBP1 on GR activity [167]. </plain></SENT>
<SENT sid="17983" pm="."><plain>However, Cyp40 was unable to oppose the trans-inhibitory effects of FKBP1 [134]. </plain></SENT>
<SENT sid="17984" pm="."><plain>Recently another member of the FKBP family has emerged FKBP-like or FKBPL that may have high significance in cancer [138, 168, 169]. </plain></SENT>
<SENT sid="17985" pm="."><plain>FKBPL has a conserved TPR domain although the PPIase domain is divergent compared with FKPP1, 2 [138]. <p><text><SENT sid="17986" pm="."><plain>As mentioned above-immunophilins appear to be significant in hormone-dependent cancer, and FKBP1 in particular is enriched in prostate cancer as opposed to benign tumors and stimulates androgen-dependent transcription and growth [164–166, 170, 171]. </plain></SENT>
<SENT sid="17987" pm="."><plain>FKBP2 appears to play a role in breast cancer and treatment with estradiol led to a 14-fold increase in expression [166]. </plain></SENT>
<SENT sid="17988" pm="."><plain>FKBPL is associated with ER in breast cancer, and increased levels of the protein indicate a good prognosis in the case of this disease [138]. <p><text><SENT sid="17989" pm="."><plain>TTC4. Tetraticopeptide 4 (TTC4) is another TPR domain protein and was originally discovered in a screen for loss of heterozygosity in the chromosomal 1p31 region associated with breast cancer and was thus implicated as a tumor suppressor gene [148, 149]. </plain></SENT>
<SENT sid="17990" pm="."><plain>TTC4 appears to function in the nucleus and has been implicated as a component of a complex containing the histone acetyltransferase MYST/MOF and in the assembly of transcriptional initiation factor TFIIIB [149–152]. </plain></SENT>
<SENT sid="17991" pm="."><plain>TTC4 is also a potential Hsp90 binding protein and appears to have an important role in linking Hsp90 function to replication [153], TTC4 may thus have a role in multiple nuclear functions including transcription and replication and these may be linked to its tumor suppressor properties. <p><text><SENT sid="17992" pm="."><plain>TTC5. Tetraticopeptide 5 (TTC5) also known as stress-responsive activator of p300 (Strap) contains six TPR domains, and with these multiple interaction domains could thus play a role as a scaffold protein in a similar way to Hop [87, 88]. </plain></SENT>
<SENT sid="17993" pm="."><plain>TTC5/Strap binds to the histone acetylase p300 and is implicated in the activation of transcription in response to stresses such as DNA damage and heat shock [88, 154, 155]. </plain></SENT>
<SENT sid="17994" pm="."><plain>p300 is a cofactor for a wide range of transcription factors, as well as forming complexes with an array of other proteins and can modify both the associated factors as well as histone H4 by acetylation [156]. </plain></SENT>
<SENT sid="17995" pm="."><plain>Indeed, TTC5/Strap is implicated in the regulation of GR as with other co-chaperones such as Cyp40, FKBP1, and FKBP2 and could potentially couple molecular chaperones and stress to transcriptional activation [157]. </plain></SENT>
<SENT sid="17996" pm="."><plain>TTC5/Strap may thus play a role in transcriptional regulation during stress responses to heat shock or DNA damage although currently no evidence appears to link this co-chaperone to cancer. <p><text><SENT sid="17997" pm="."><plain>XAP2/AIP. Another TPR domain containing Hsp90 binding co-chaperone is XAP2, also known as AIP [158]. </plain></SENT>
<SENT sid="17998" pm="."><plain>This protein is a member of the immunophilin family and regulates activity of steroid hormone receptors such as the aryl hydrocarbon receptor and the estrogen receptor α (ERα) [159, 160]. </plain></SENT>
<SENT sid="17999" pm="."><plain>The co-chaperone could potentially play a role in breast cancer through its negative regulation of ERα [159]. </plain></SENT>
<SENT sid="18000" pm="."><plain>ER can stimulate mammary cancer growth but can also function as an inhibitor of metastasis, and its exact role in cancer would thus be difficult to predict [161]. </sec><sec id="sec5"><title><text><SENT sid="18001" pm="."><plain>5. </plain></SENT>
<SENT sid="18002" pm="."><plain>Overview: Cochaperones and Cancer </plain></SENT>
</text></title><p><text><SENT sid="18003" pm="."><plain>As co-chaperones are essential for significant molecular chaperone activity in vitro, one might predict a uniform procancer role for these molecules as with the primary chaperones. However, their role in cancer appears to be complex. It is thus evident that a number of co-chaperones are overexpressed in cancers and signal a poor prognosis in patients and may be candidates for the development of novel approaches to cancer therapy. Hop, p23, p50/Cdc37, Aha1, FKBP1, and FKBP2 appear to be intimately involved in the chaperoning of molecules involved in cancer incidence and progression (Figure 3). </plain></SENT>
<SENT sid="18007" pm="."><plain>Cancers appear to become addicted to these co-chaperones in a similar way to their dependence on the primary chaperones, requiring these co-factors to maintain elevated levels of oncogenes which are often mutated during carcinogenesis [18, 21]. </plain></SENT>
<SENT sid="18008" pm="."><plain>In addition, the BAG domain proteins appear to indicate a poor prognosis for cancer patients due to their inhibition of apoptosis—one of the key hallmarks of cancer [172, 173]. </plain></SENT>
<SENT sid="18009" pm="."><plain>However, a sizable number of the co-chaperones, including HspBP1, the JDP family proteins, FKBPL, and TTC4 appear to signal a good prognosis in cancer suggesting that they may have tumor suppressive functions (Figure 3). </plain></SENT>
<SENT sid="18010" pm="."><plain>As mentioned above, TTC4 in particular was identified in a loss of heterozygosity screen for tumor suppressor genes. </sec><SecTag type="METHODS"><sec id="sec6"><title><text><SENT sid="18011" pm="."><plain>6. </plain></SENT>
<SENT sid="18012" pm="."><plain>Molecular Chaperones and Cochaperones in Cancer Treatment </plain></SENT>
</text></title><p><text><SENT sid="18013" pm="."><plain>The targeting of Hsp90 in cancer was initially stimulated by the availability of drugs such as geldanamycin and radicicol that bind to and inhibit its ATPase domain [174, 175]. </plain></SENT>
<SENT sid="18014" pm="."><plain>Hsp90 has since become a heavily targeted molecule, and several generations of anticancer drugs including the 17-allylamino-17-demethoxygeldanomycin (17-AAG) showed promise in cancer treatment [176, 177]. </plain></SENT>
<SENT sid="18015" pm="."><plain>More modern synthetic drugs have recently become available that have solved some of the early problems with drug toxicity, and progress in this area can be expected [174]. </plain></SENT>
<SENT sid="18016" pm="."><plain>Hsp70/HSPA family members also have considerable promise as targets in cancer and proteins such as Hsp72, Hsp70.2, and mortalin are increased in breast cancer and when inhibited elicit apoptosis [178–180]. </plain></SENT>
<SENT sid="18017" pm="."><plain>In addition, the Hsp70 family members appear essential in chaperoning oncogenic proteins as is observed with Hsp90, and compounds capable of inhibiting the Hsp70 chaperones are beginning to emerge [181]. </plain></SENT>
<SENT sid="18018" pm="."><plain>In addition, a recent pharmacological study of AR signaling using gene expression profiling indicated two more classes of drugs that might inhibit chaperone/co-chaperone interactions. Two drug families, centering on the natural compounds celastrol and gedunin, were uncovered [182]. </plain></SENT>
<SENT sid="18020" pm="."><plain>Celastrol was shown to disrupt the function of the Hsp90/Cdc37 complex, a key growth-requiring pathway in prostate cancer and thus is a promising agent for this disease [183]. </plain></SENT>
<SENT sid="18021" pm="."><plain>The drug is however somewhat lacking in specificity and also directly inhibits IκB kinase and the proteasome as well as activating HSF1 [184]. </plain></SENT>
<SENT sid="18022" pm="."><plain>As mentioned above, gedunin inhibits p23, another prooncogenic Hsp90 co-chaperone [115]. </plain></SENT>
<SENT sid="18023" pm="."><plain>Therefore, although in its infancy, the concept of targeting co-chaperones in cancer treatment seems feasible and practical. </sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgment</title><p><text4fund><text><SENT sid="18024" pm="."><plain>This work was supported by NIH Research Grants RO-1CA047407, R01CA119045, and RO-1CA094397. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="18025" pm="."><plain>1LindquistSCraigEAThe heat-shock proteinsAnnual Review of Genetics1988226316772-s2.0-0024151897 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="18026" pm="."><plain>2EllisRJProtein misassembly: macromolecular crowding and molecular chaperonesAdvances in Experimental Medicine and Biology20075941132-s2.0-3384692407417205670 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="18027" pm="."><plain>3MayerMPBukauBHsp70 chaperones: cellular functions and molecular mechanismCellular and Molecular Life Sciences20056266706842-s2.0-1704438738615770419 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="18028" pm="."><plain>4GuisbertEHermanCLuCZGrossCAA chaperone network controls the heat shock response in E. coli Genes and Development20041822281228212-s2.0-864429087415545634 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="18029" pm="."><plain>5LiberekKSkowyraDZyliczMJohnsonCGeorgopoulosCThe Escherichia coli DnaK chaperone, the 70-kDa heat shock protein eukaryotic equivalent, changes conformation upon ATP hydrolysis, thus triggering its dissociation from a bound target proteinThe Journal of Biological Chemistry19912662214491144962-s2.0-00263202961830586 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="18030" pm="."><plain>6KampingaHHHagemanJVosMJGuidelines for the nomenclature of the human heat shock proteinsCell Stress and Chaperones20091411051112-s2.0-6454909743918663603 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="18031" pm="."><plain>7CraigEAThe heat shock responseCRC Critical Reviews in Biochemistry19851832392802-s2.0-00217764172412760 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="18032" pm="."><plain>8CalderwoodSKXieYWangXSignal transduction pathways leading to heat shock transcriptionSignal Transduction Insights20102132421687820 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="18033" pm="."><plain>9RitossaFMExperimental activation of specific loci in polytene chromosomes of DrosophilaExperimental Cell Research19643536016072-s2.0-000491515314208747 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="18034" pm="."><plain>10RitossaFA new puffing pattern induced by temperature shock and DNP in DrosophilaExperientia196218125715732-s2.0-34250561475 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="18035" pm="."><plain>11ZhangYCalderwoodSKAutophagy, protein aggregation and hyperthermia: a mini-reviewInternational Journal of Hyperthermia20112754094142-s2.0-7996042916321756038 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="18036" pm="."><plain>12LiGCWerbZCorrelation between synthesis of heat shock proteins and development of thermotolerance in Chinese hamster fibroblastsProceedings of the National Academy of Sciences of the United States of America19827910321832222-s2.0-00201308776954473 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="18037" pm="."><plain>13SubjeckJRSciandraJJJohnsonRJHeat shock proteins and thermotolerance; a comparison of induction kineticsThe British Journal of Radiology1982556565795842-s2.0-00199586517116088 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="18038" pm="."><plain>14GabaiVLMeriinABMosserDDHsp70 prevents activation of stress kinases: a novel pathway of cellular thermotoleranceThe Journal of Biological Chemistry19972722918033180372-s2.0-00307460539218432 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="18039" pm="."><plain>15ShermanMYGoldbergALCellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseasesNeuron200129115322-s2.0-003513910911182078 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="18040" pm="."><plain>16WinklhoferKFTatzeltJHaassCThe two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseasesEMBO Journal20082723363492-s2.0-3854916953018216876 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="18041" pm="."><plain>17CalderwoodSKMurshidAPrinceTThe shock of aging: molecular chaperones and the heat shock response in longevity and aging—a mini-reviewGerontology20095555505582-s2.0-7034950734019546513 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="18042" pm="."><plain>18WhitesellLLindquistSLHSP90 and the chaperoning of cancerNature Reviews Cancer20055107617722-s2.0-2584451955016175177 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="18043" pm="."><plain>19CioccaDRArrigoAPCalderwoodSKHeat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an updateArchives of Toxicology2013871194822885793 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="18044" pm="."><plain>20CioccaDRCalderwoodSKHeat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implicationsCell Stress and Chaperones2005102861032-s2.0-2174444506916038406 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="18045" pm="."><plain>21TrepelJMollapourMGiacconeGNeckersLTargeting the dynamic HSP90 complex in cancerNature Reviews Cancer20101085375492-s2.0-7795494533320651736 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="18046" pm="."><plain>22NeckersLHsp90 inhibitors as novel cancer chemotherapeutic agentsTrends in Molecular Medicine200284S55S612-s2.0-003621960911927289 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="18047" pm="."><plain>23GabaiVLYaglomJAWaldmanTShermanMYHeat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cellsMolecular and Cellular Biology20092925595692-s2.0-5824911055719001088 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="18048" pm="."><plain>24O’Callaghan-SunolCGabaiVLShermanMYHsp27 modulates p53 signaling and suppresses cellular senescenceCancer Research2007672411779117882-s2.0-3754902545518089808 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="18049" pm="."><plain>25BeereHM‘The stress of dying’: the role of heat shock proteins in the regulation of apoptosisJournal of Cell Science200411713264126512-s2.0-324287918815169835 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="18050" pm="."><plain>26WuCHeat shock transcription factors: structure and regulationAnnual Review of Cell and Developmental Biology1995114414692-s2.0-0029564954 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="18051" pm="."><plain>27DaiCWhitesellLRogersABLindquistSHeat shock factor 1 is a powerful multifaceted modifier of carcinogenesisCell20071306100510182-s2.0-3454865823017889646 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="18052" pm="."><plain>28KhalequeMABhartiAGongJHeat shock factor 1 represses estrogen-dependent transcription through association with MTA1Oncogene20082713188618932-s2.0-4114908349517922035 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="18053" pm="."><plain>29KhalequeMABhartiASawyerDInduction of heat shock proteins by heregulin β1 leads to protection from apoptosis and anchorage-independent growthOncogene20052443656465732-s2.0-2694444244416007186 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="18054" pm="."><plain>30SantagataSHuRLinNUHigh levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancerProceedings of the National Academy of Sciences of the United States of America201110845183781838322042860 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="18055" pm="."><plain>31CalderwoodSKHSF1, a versatile factor in tumorogenesisCurrent Molecular Medicine20121291102110722804234 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="18056" pm="."><plain>32JohnsonJLEvolution and function of diverse Hsp90 homologs and cochaperone proteinsBiochimica et Biophysica Acta20121823360761322008467 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="18057" pm="."><plain>33RampeltHMayerMPBukauBNucleotide exchange factors for Hsp70 chaperonesMethods in Molecular Biology2011787839121898229 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="18058" pm="."><plain>34YoungJCAgasheVRSiegersKHartlFUPathways of chaperone-mediated protein folding in the cytosolNature Reviews Molecular Cell Biology20045107817912-s2.0-504423910715459659 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="18059" pm="."><plain>35YoungJCBarralJMHartlFUMore than folding: localized functions of cytosolic chaperonesTrends in Biochemical Sciences200328105415472-s2.0-064237746614559183 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="18060" pm="."><plain>36da SilvaKPBorgesJCThe molecular chaperone Hsp70 family members function by a bidirectional heterotrophic allosteric mechanismProtein and Peptide Letters20111821321422-s2.0-7995215849221121894 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="18061" pm="."><plain>37FlahertyKMDeLuca-FlahertyCMcKayDBThree-dimensional structure of the ATPase fragment of a 70K heat-shock cognate proteinNature199034662856236282-s2.0-00251003722143562 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="18062" pm="."><plain>38FlynnGCChappellTGRothmanJEPeptide binding and release by proteins implicated as catalysts of protein assemblyScience198924549163853902-s2.0-00243937782756425 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="18063" pm="."><plain>39SchlechtRErbseAHBukauBMayerMPMechanics of Hsp70 chaperones enables differential interaction with client proteinsNature Structural and Molecular Biology20111833453512-s2.0-79952364237 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="18064" pm="."><plain>40SharmaSKChristenPGoloubinoffPDisaggregating chaperones: an unfolding storyCurrent Protein and Peptide Science20091054324462-s2.0-7034948486119538153 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="18065" pm="."><plain>41ChappleJPvan der SpuyJPoopalasundaramSCheethamMENeuronal DnaJ proteins HSJ1a and HSJ1b: a role in linking the Hsp70 chaperone machine to the ubiquitin-proteasome system?Biochemical Society Transactions20043246406422-s2.0-434468421515270696 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="18066" pm="."><plain>42HennessyFCheethamMEDirrHWBlatchGLAnalysis of the levels of conservation of the J domain among the various types of DnaJ-like proteinsCell Stress and Chaperones2000543473582-s2.0-003367015411048657 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="18067" pm="."><plain>43HennessyFNicollWSZimmermannRCheethamMEBlatchGLNot all J domains are created equal: implications for the specificity of Hsp40-Hsp70 interactionsProtein Science2005147169717092-s2.0-2234444703515987899 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="18068" pm="."><plain>44SterrenbergJNBlatchGLEdkinsALHuman DNAJ in cancer and stem cellsCancer Letters2011312212914221925790 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="18069" pm="."><plain>45TsukaharaFMaruYBag1 directly routes immature BCR-ABL for proteasomal degradationBlood201011618358235922-s2.0-7814929476520675402 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="18070" pm="."><plain>46RosatiAGrazianoVde LaurenziVPascaleMTurcoMCBAG3: a multifaceted protein that regulates major cell pathwaysCell Death and Disease201124, article e1412-s2.0-79960008971 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="18071" pm="."><plain>47TakayamaSXieZReedJCAn evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulatorsThe Journal of Biological Chemistry199927427817862-s2.0-00335345889873016 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="18072" pm="."><plain>48TakayamaSReedJCMolecular chaperone targeting and regulation by BAG family proteinsNature Cell Biology2001310E237E2412-s2.0-003479076811584289 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="18073" pm="."><plain>49KabaniMMcLellanCRaynesDAGuerrieroVBrodskyJLHspBP1, a homologue of the yeast Fes1 and Sls1 proteins, is an Hsc70 nucleotide exchange factorFEBS Letters200253123393422-s2.0-003703247012417338 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="18074" pm="."><plain>50KabaniMBeckerichJMBrodskyJLNucleotide exchange factor for the yeast Hsp70 molecular chaperone Ssa1pMolecular and Cellular Biology20022213467746892-s2.0-003627566312052876 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="18075" pm="."><plain>51ScheuflerCBrinkerABourenkovGStructure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machineCell200010121992102-s2.0-003464651110786835 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="18076" pm="."><plain>52WegeleHHaslbeckMReinsteinJBuchnerJSti1 is a novel activator of the Ssa proteinsThe Journal of Biological Chemistry20032782825970259762-s2.0-003783058612716905 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="18077" pm="."><plain>53ProdromouCSiligardiGO’BrienRRegulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperonesEMBO Journal19991837547622-s2.0-00330819689927435 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="18078" pm="."><plain>54BallingerCAConnellPWuYIdentification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functionsMolecular and Cellular Biology1999196453545452-s2.0-003301312610330192 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="18079" pm="."><plain>55LiberekKGeorgopoulosCZyliczMRole of the Escherichia coli DnaK and DnaJ heat shock proteins in the initiation of bacteriophage λ DNA replicationProceedings of the National Academy of Sciences of the United States of America19888518663266362-s2.0-00127494582970643 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="18080" pm="."><plain>56PanaretouBProdromouCRoeSMATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivoEMBO Journal19981716482948362-s2.0-00325413449707442 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="18081" pm="."><plain>57JacksonSEHsp90: structure and functionTopics in Current Chemistry201332815524022955504 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="18082" pm="."><plain>58RosserMFNTrottaBMMarshallMRBerwinBNicchittaCVAdenosine nucleotides and the regulation of GRP94-client protein interactionsBiochemistry20044327883588452-s2.0-304277753715236592 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="18083" pm="."><plain>59AltieriDCSteinGSLianJBLanguinoLRTRAP-1, the mitochondrial Hsp90Biochimica et Biophysica Acta20121823376777321878357 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="18084" pm="."><plain>60FeltsSJOwenBALNguyenPTrepelJDonnerDBToftDOThe hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional propertiesThe Journal of Biological Chemistry20002755330533122-s2.0-003460317810652318 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="18085" pm="."><plain>61NeckersLIvySPHeat shock protein 90Current Opinion in Oncology20031564194242-s2.0-074228726414624223 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="18086" pm="."><plain>62WorkmanPBurrowsFNeckersLRosenNDrugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stressAnnals of the New York Academy of Sciences200711132022162-s2.0-3534889098117513464 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="18087" pm="."><plain>63PrattWBToftDORegulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machineryExperimental Biology and Medicine200322821111332-s2.0-003731520812563018 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="18088" pm="."><plain>64AliMMUMark RoeSVaughanCKCrystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complexNature20064407087101310172-s2.0-3364617624616625188 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="18089" pm="."><plain>65MeyerPProdromouCHuBStructural and functional analysis of the middle segment of Hsp90: implications for ATP hydrolysis and client protein and cochaperone interactionsMolecular Cell20031136476582-s2.0-003735244612667448 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="18090" pm="."><plain>66WayneNBolonDNDimerization of Hsp90 is required for in vivo function: design and analysis of monomers and dimersThe Journal of Biological Chemistry20072824835386353952-s2.0-3684908394717908693 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="18091" pm="."><plain>67WayneNMishraPBolonDNHsp90 and client protein maturationMethods in Molecular Biology2011787334421898225 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="18092" pm="."><plain>68CoxMBJohnsonJLThe role of p23, Hop, immunophilins, and other co-chaperones in regulating Hsp90 functionMethods in Molecular Biology2011787456621898226 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="18093" pm="."><plain>69VaughanCKGohlkeUSobottFStructure of an Hsp90-Cdc37-Cdk4 complexMolecular Cell20062356977072-s2.0-3374787871716949366 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="18094" pm="."><plain>70McLaughlinSHSobottFYaoZPThe co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteinsJournal of Molecular Biology200635637467582-s2.0-3134447455816403413 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="18095" pm="."><plain>71RichterKWalterSBuchnerJThe co-chaperone Sba1 connects the ATPase reaction of Hsp90 to the progression of the chaperone cycleJournal of Molecular Biology20043425140314132-s2.0-444429174315364569 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="18096" pm="."><plain>72GrammatikakisNLinJHGrammatikakisATsichlisPNCochranBHp50(cdc37) acting in concert with Hsp90 is required for Raf-1 functionMolecular and Cellular Biology1999193166116722-s2.0-003305590810022854 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="18097" pm="."><plain>73GrayPJJr.PrinceTChengJStevensonMACalderwoodSKTargeting the oncogene and kinome chaperone CDC37Nature Reviews Cancer2008874914952-s2.0-4584913162318511936 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="18098" pm="."><plain>74MandalAKTheodorakiMANillegodaNBCaplanAJRole of molecular chaperones in biogenesis of the protein kinomeMethods in Molecular Biology20127877581 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="18099" pm="."><plain>75MattsRCaplanAJCdc37 and Protein Kinase Folding2007Dordrecht, The NetherlandsSpringer </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="18100" pm="."><plain>76CatlettMGKaplanKBSgt1p is a unique co-chaperone that acts as a client adaptor to link Hsp90 to Skp1pThe Journal of Biological Chemistry20062814433739337482-s2.0-3384595914916945921 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="18101" pm="."><plain>77MayerMPNikolayRBukauBAha, another regulator for Hsp90 chaperonesMolecular Cell2002106125512562-s2.0-003692390512503997 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="18102" pm="."><plain>78RetzlaffMHagnFMitschkeLAsymmetric activation of the Hsp90 dimer by its cochaperone Aha1Molecular Cell20103733443542-s2.0-7594910617320159554 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="18103" pm="."><plain>79van der SpuyJCheethamMEDirrHWBlatchGLThe cochaperone murine stress-inducible protein 1: overexpression, purification, and characterizationProtein Expression and Purification20012134624692-s2.0-003571500211281722 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="18104" pm="."><plain>80SchmidABLaglederSGrawertMAThe architecture of functional modules in the Hsp90 co-chaperone Sti1/HopEMBO Journal2012311506151722227520 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="18105" pm="."><plain>81ZhangMWindheimMRoeSMChaperoned ubiquitylation—crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complexMolecular Cell20052045255382-s2.0-2794449529916307917 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="18106" pm="."><plain>82StankiewiczMNikolayRRybinVMayerMPCHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substratesFEBS Journal201027716335333672-s2.0-7795525761720618441 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="18107" pm="."><plain>83CarraSSeguinSJLandryJHspB8 and Bag3: a new chaperone complex targeting misfolded proteins to macroautophagyAutophagy2008422372392-s2.0-3894918424118094623 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="18108" pm="."><plain>84GamerdingerMKayaAMWolfrumUClementAMBehlCBAG3 mediates chaperone-based aggresome-targeting and selective autophagy of misfolded proteinsEMBO Reports20111221491562-s2.0-7955160933221252941 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="18109" pm="."><plain>85DuinaAAMarshJAKurtzRBChangHCJLindquistSGaberRFThe peptidyl-prolyl isomerase domain of the CyP-40 cyclophilin homolog Cpr7 is not required to support growth or glucocorticoid receptor activity in Saccharomyces cerevisiae The Journal of Biological Chemistry19982731810819108222-s2.0-00320795399556552 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="18110" pm="."><plain>86MokDAllanRKCarrelloAWangooKWalkinshawMDRatajczakTThe chaperone function of cyclophilin 40 maps to a cleft between the prolyl isomerase and tetratricopeptide repeat domainsFEBS Letters200658011276127682-s2.0-3364657883716650407 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="18111" pm="."><plain>87DemonacosCKrstic-DemonacosMla ThangueNBA TPR motif cofactor contributes to p300 activity in the p53 responseMolecular Cell20018171842-s2.0-003489285411511361 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="18112" pm="."><plain>88DemonacosCKrstic-DemonacosMSmithLA new effector pathway links ATM kinase with the DNA damage responseNature Cell Biology20046109689762-s2.0-544427177415448695 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="18113" pm="."><plain>89BriveLTakayamaSBriknarováKThe carboxyl-terminal lobe of Hsc70 ATPase domain is sufficient for binding to BAG1Biochemical and Biophysical Research Communications20012895109911052-s2.0-003593100311741305 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="18114" pm="."><plain>90StuartJKMyszkaDGJossLCharacterization of interactions between the anti-apoptotic protein BAG-1 and Hsc70 molecular chaperonesThe Journal of Biological Chemistry19982733522506225142-s2.0-00325756439712876 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="18115" pm="."><plain>91FranceschelliSRosatiALeroseRde NicolaSTurcoMCPascaleMbag3 gene expression is regulated by heat shock factor 1Journal of Cellular Physiology200821535755772-s2.0-4294917953018286539 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="18116" pm="."><plain>92AveicSPigazziMBassoGBAG1: the guardian of anti-apoptotic proteins in acute myeloid leukemiaPLoS ONE2011610e26097 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="18117" pm="."><plain>93AmmiranteMRosatiAArraCIKKγ protein is a target of BAG3 regulatory activity in human tumor growthProceedings of the National Academy of Sciences of the United States of America201010716749775022-s2.0-7795211242520368414 </plain></SENT>
</text></ref><ref id="B94"><text><SENT sid="18118" pm="."><plain>94ShomuraYDragovicZChangHCRegulation of Hsp70 function by HspBP1: structural analysis reveals an alternate mechanism for Hsp70 nucleotide exchangeMolecular Cell20051733673792-s2.0-1324427804315694338 </plain></SENT>
</text></ref><ref id="B95"><text><SENT sid="18119" pm="."><plain>95AlbertiSBöhseKArndtVSchmitzAHöhfeldJThe cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulatorMolecular Biology of the Cell2004159400340102-s2.0-434457853415215316 </plain></SENT>
</text></ref><ref id="B96"><text><SENT sid="18120" pm="."><plain>96SouzaAPAlbuquerqueCTorronteguyCHspBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressivenessCell Stress and Chaperones20091433013102-s2.0-6614915065218987994 </plain></SENT>
</text></ref><ref id="B97"><text><SENT sid="18121" pm="."><plain>97TanimuraSHiranoAIHashizumeJAnticancer drugs up-regulate HspBP1 and thereby antagonize the prosurvival function of Hsp70 in tumor cellsThe Journal of Biological Chemistry20072824935430354392-s2.0-3724901792417855353 </plain></SENT>
</text></ref><ref id="B98"><text><SENT sid="18122" pm="."><plain>98FehrenbacherNJäätteläMLysosomes as targets for cancer therapyCancer Research2005658299329952-s2.0-1714436182015833821 </plain></SENT>
</text></ref><ref id="B99"><text><SENT sid="18123" pm="."><plain>99NylandstedJGyrd-HansenMDanielewiczAHeat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilizationJournal of Experimental Medicine200420044254352-s2.0-434465131815314073 </plain></SENT>
</text></ref><ref id="B100"><text><SENT sid="18124" pm="."><plain>100StrausDWalterWGrossCADnaK, DnaJ, and GrpE heat shock proteins negatively regulate heat shock gene expression by controlling the synthesis and stability of σ32Genes and Development1990412220222092-s2.0-00256329732269429 </plain></SENT>
</text></ref><ref id="B101"><text><SENT sid="18125" pm="."><plain>101IsomotoHOkaMYanoYExpression of heat shock protein (Hsp) 70 and Hsp 40 in gastric cancerCancer Letters200319822192282-s2.0-1774441611212957361 </plain></SENT>
</text></ref><ref id="B102"><text><SENT sid="18126" pm="."><plain>102MitraAFillmoreRAMetgeBJLarge isoform of MRJ (DNAJB6) reduces malignant activity of breast cancerBreast Cancer Research2008102, article R222-s2.0-48949119506 </plain></SENT>
</text></ref><ref id="B103"><text><SENT sid="18127" pm="."><plain>103MitraAShevdeLASamantRSMulti-faceted role of HSP40 in cancerClinical and Experimental Metastasis20092665595672-s2.0-6804913941619340594 </plain></SENT>
</text></ref><ref id="B104"><text><SENT sid="18128" pm="."><plain>104CanamasasIDebesANataliPGKurzik-DumkeUUnderstanding human cancer using Drosophila. Tid47, a cytosolic product of the DnaJ-like tumor suppressor gene l(2)tid, is a novel molecular partner of patched related to skin cancerThe Journal of Biological Chemistry20032783330952309602-s2.0-004273316912783860 </plain></SENT>
</text></ref><ref id="B105"><text><SENT sid="18130" pm="."><plain>105Kurzik-DumkeUGundackerDRentropMGateffETumor suppression in Drosophila is causally related to the function of the lethal(2)tumorous imaginal discs gene, a dnaJ homologDevelopmental Genetics199516164762-s2.0-00289626297758246 </plain></SENT>
</text></ref><ref id="B106"><text><SENT sid="18131" pm="."><plain>106CarriganPESikkinkLASmithDFRamirez-AlvaradoMDomain:domain interactions within Hop, the Hsp70/Hsp90 organizing protein, are required for protein stability and structureProtein Science20061535225322-s2.0-3364450016316452615 </plain></SENT>
</text></ref><ref id="B107"><text><SENT sid="18132" pm="."><plain>107KubotaHYamamotoSItohEIncreased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinomaCell Stress and Chaperones2010156100310112-s2.0-7814946515620617406 </plain></SENT>
</text></ref><ref id="B108"><text><SENT sid="18133" pm="."><plain>108SunWXingBSunYProteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresisMolecular and Cellular Proteomics2007610179818082-s2.0-3564896362717627933 </plain></SENT>
</text></ref><ref id="B109"><text><SENT sid="18134" pm="."><plain>109WalshNLarkinASwanNRNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulationCancer Letters201130621801892-s2.0-7995547870421470770 </plain></SENT>
</text></ref><ref id="B110"><text><SENT sid="18135" pm="."><plain>110FreemanBCFeltsSJToftDOYamamotoKRThe p23 molecular chaperones act at a late step in intracellular receptor action to differentially affect ligand efficaciesGenes and Development20001444224342-s2.0-003410233910691735 </plain></SENT>
</text></ref><ref id="B111"><text><SENT sid="18136" pm="."><plain>111SimpsonNELambertWMWatkinsRHigh levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistanceCancer Research20107021844684562-s2.0-7844929442520847343 </plain></SENT>
</text></ref><ref id="B112"><text><SENT sid="18137" pm="."><plain>112ReebyeVCanoLQLaveryDNRole of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancerMolecular Endocrinology201226101694170622899854 </plain></SENT>
</text></ref><ref id="B113"><text><SENT sid="18138" pm="."><plain>113PrinceTNeckersLA network of its own: the unique interactome of the Hsp90 cochaperone, Sba1/p23Molecular Cell20114321591602-s2.0-7996046341521777805 </plain></SENT>
</text></ref><ref id="B114"><text><SENT sid="18139" pm="."><plain>114LiuXZouLZhuLmiRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemiaLeukemia Research20123691098110422677230 </plain></SENT>
</text></ref><ref id="B115"><text><SENT sid="18140" pm="."><plain>115PatwardhanCAFauqAPetersonLBMillerCBlaggBSChadliAGedunin inactivates the co-chaperone p23 causing cancer cell death by apoptosisThe Journal of Biological Chemistry2013288107313732523355466 </plain></SENT>
</text></ref><ref id="B116"><text><SENT sid="18141" pm="."><plain>116ZabkaMLeśniakWPrusWKuźnickiJFilipekASgt1 has co-chaperone properties and is up-regulated by heat shockBiochemical and Biophysical Research Communications200837011791832-s2.0-4184909366318358234 </plain></SENT>
</text></ref><ref id="B117"><text><SENT sid="18142" pm="."><plain>117StuttmannJParkerJENoëlLDStaying in the fold: the SGT1/chaperone machinery in maintenance and evolution of leucine-rich repeat proteinsPlant Signaling and Behavior2008352832852-s2.0-4324909855819513219 </plain></SENT>
</text></ref><ref id="B118"><text><SENT sid="18143" pm="."><plain>118ZhangMKadotaYProdromouCShirasuKPearlLHStructural basis for assembly of Hsp90-Sgt1-CHORD protein complexes: implications for chaperoning of NLR innate immunity receptorsMolecular Cell20103922692812-s2.0-7795548098120670895 </plain></SENT>
</text></ref><ref id="B119"><text><SENT sid="18144" pm="."><plain>119DaviesAEKaplanKBHsp90-Sgt1 and Skp1 target human Mis12 complexes to ensure efficient formation of kinetochore-microtubule binding sitesJournal of Cell Biology201018922612742-s2.0-7795119847720404110 </plain></SENT>
</text></ref><ref id="B120"><text><SENT sid="18145" pm="."><plain>120StepanovaLFinegoldMDeMayoFSchmidtEVHarperJWThe oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissuesMolecular and Cellular Biology20002012446244732-s2.0-003408705110825210 </plain></SENT>
</text></ref><ref id="B121"><text><SENT sid="18146" pm="."><plain>121StepanovaLYangGDeMayoFInduction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasiaOncogene20001918218621932-s2.0-003472025510822368 </plain></SENT>
</text></ref><ref id="B122"><text><SENT sid="18147" pm="."><plain>122CasasSOllilaJAventínAVihinenMSierraJKnuutilaSChanges in apoptosis-related pathways in acute myelocytic leukemiaCancer Genetics and Cytogenetics20031462891012-s2.0-014152746014553942 </plain></SENT>
</text></ref><ref id="B123"><text><SENT sid="18148" pm="."><plain>123FeoFde MiglioMRSimileMMHepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predispositionBiochimica et Biophysica Acta2006176521261472-s2.0-3364613917416216419 </plain></SENT>
</text></ref><ref id="B124"><text><SENT sid="18150" pm="."><plain>124KatayamaYSakaiAOkikawaYCyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cellsInternational Journal of Oncology20042535795952-s2.0-1544437658115289859 </plain></SENT>
</text></ref><ref id="B125"><text><SENT sid="18151" pm="."><plain>125ThompsonMAStumphJHenricksonSEDifferential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomasHuman Pathology20053654945042-s2.0-2014438562515948116 </plain></SENT>
</text></ref><ref id="B126"><text><SENT sid="18152" pm="."><plain>126CaplanAJMandalAKTheodorakiMAMolecular chaperones and protein kinase quality controlTrends in Cell Biology200717287922-s2.0-3384665128217184992 </plain></SENT>
</text></ref><ref id="B127"><text><SENT sid="18153" pm="."><plain>127MandalAKLeePChenJACdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturationJournal of Cell Biology200717633193282-s2.0-3384658843617242065 </plain></SENT>
</text></ref><ref id="B128"><text><SENT sid="18154" pm="."><plain>128GrayPJJr.StevensonMACalderwoodSKTargeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cellsCancer Research2007672411942119502-s2.0-3754906072018089825 </plain></SENT>
</text></ref><ref id="B129"><text><SENT sid="18155" pm="."><plain>129SmithJRClarkePADe BillyEWorkmanPSilencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitorsOncogene20092821571692-s2.0-5824911289818931700 </plain></SENT>
</text></ref><ref id="B130"><text><SENT sid="18156" pm="."><plain>130RobzykKOenHBuchananGUncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptorMolecular and Cellular Endocrinology20072681-267742-s2.0-3394730163317336451 </plain></SENT>
</text></ref><ref id="B131"><text><SENT sid="18157" pm="."><plain>131PearlLHProdromouCStructure, function, and mechanism of the Hsp90 molecular chaperoneAdvances in Protein Chemistry2001591571862-s2.0-003571889911868271 </plain></SENT>
</text></ref><ref id="B132"><text><SENT sid="18158" pm="."><plain>132SuAIWiltshireTBatalovSA gene atlas of the mouse and human protein-encoding transcriptomesProceedings of the National Academy of Sciences of the United States of America200410116606260672-s2.0-1114435819815075390 </plain></SENT>
</text></ref><ref id="B133"><text><SENT sid="18159" pm="."><plain>133HolmesJLSharpSYHobbsSWorkmanPSilencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycinCancer Research2008684118811972-s2.0-4044908978918281495 </plain></SENT>
</text></ref><ref id="B134"><text><SENT sid="18160" pm="."><plain>134SchülkeJPWochnikGMLang-RollinIDifferential impact of tetratricopeptide repeat proteins on the steroid hormone receptorsPloS ONE201057p. e117172-s2.0-78049385146 </plain></SENT>
</text></ref><ref id="B149"><text><SENT sid="18162" pm="."><plain>135ScammellJGDennyWBValentineDLSmithDFOverexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primatesGeneral and Comparative Endocrinology200112421521652-s2.0-003516950311703081 </plain></SENT>
</text></ref><ref id="B150"><text><SENT sid="18163" pm="."><plain>136DennyWBValentineDLReynoldsPDSmithDFScammellJGSquirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor bindingEndocrinology200014111410741132-s2.0-003371228011089542 </plain></SENT>
</text></ref><ref id="B151"><text><SENT sid="18164" pm="."><plain>137RiggsDLCoxMBTardifHLHesslingMBuchnerJSmithDFNoncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signalingMolecular and Cellular Biology20072724865886692-s2.0-3754906773117938211 </plain></SENT>
</text></ref><ref id="B155"><text><SENT sid="18165" pm="."><plain>138McKeenHDBrennanDJHegartySThe emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPLBiochemical Society Transactions20113926636682-s2.0-7995318801621428958 </plain></SENT>
</text></ref><ref id="B135"><text><SENT sid="18166" pm="."><plain>139ChinkersMTargeting of a distinctive protein-serine phosphatase to the protein kinase-like domain of the atrial natriuretic peptide receptorProceedings of the National Academy of Sciences of the United States of America1994912311075110792-s2.0-00281177707972012 </plain></SENT>
</text></ref><ref id="B136"><text><SENT sid="18167" pm="."><plain>140HindsTDJr.StechschulteLACashHAProtein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma (PPARγ)The Journal of Biological Chemistry201128650429114292221994940 </plain></SENT>
</text></ref><ref id="B137"><text><SENT sid="18168" pm="."><plain>141HindsTDJr.SánchezERProtein phosphatase 5International Journal of Biochemistry and Cell Biology20084011235823622-s2.0-4824908998317951098 </plain></SENT>
</text></ref><ref id="B138"><text><SENT sid="18169" pm="."><plain>142MollapourMTsutsumiSTrumanAWThreonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activityMolecular Cell201141667268121419342 </plain></SENT>
</text></ref><ref id="B139"><text><SENT sid="18170" pm="."><plain>143MollapourMNeckersLPost-translational modifications of Hsp90 and their contributions to chaperone regulationBiochimica et Biophysica Acta20121823364865521856339 </plain></SENT>
</text></ref><ref id="B140"><text><SENT sid="18171" pm="."><plain>144WandingerSKSuhreMHWegeleHBuchnerJThe phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90EMBO Journal20062523673762-s2.0-3144445430216407978 </plain></SENT>
</text></ref><ref id="B141"><text><SENT sid="18172" pm="."><plain>145VaughanCKMollapourMSmithJRHsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37Molecular Cell20083168868952-s2.0-5224910849618922470 </plain></SENT>
</text></ref><ref id="B142"><text><SENT sid="18173" pm="."><plain>146WechslerTChenBPCHarperRDNA-PKcs function regulated specifically by protein phosphatase 5Proceedings of the National Academy of Sciences of the United States of America20041015124712522-s2.0-084232099514734805 </plain></SENT>
</text></ref><ref id="B143"><text><SENT sid="18174" pm="."><plain>147KangYCheongHMLeeJHProtein phosphatase 5 is necessary for ATR-mediated DNA repairBiochemical and Biophysical Research Communications201140414764812-s2.0-7865085806021144835 </plain></SENT>
</text></ref><ref id="B158"><text><SENT sid="18175" pm="."><plain>148PoetschMDittbernerTCowellJKWoenckhausCTTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skinOncogene20001950581758202-s2.0-003470692111126369 </plain></SENT>
</text></ref><ref id="B159"><text><SENT sid="18176" pm="."><plain>149SuGRobertsTCowellJKTTC4, a novel human gene containing the tetratricopeptide repeat and mapping to the region of chromosome 1p31 that is frequently deleted in sporadic breast cancerGenomics19995521571632-s2.0-00335559939933562 </plain></SENT>
</text></ref><ref id="B160"><text><SENT sid="18177" pm="."><plain>150DmitrievRIOkkelmanIAAbdulinRAShakhparonovMIPestovNBNuclear transport of protein TTC4 depends on the cell cycleCell and Tissue Research200933635215272-s2.0-6734925671019390865 </plain></SENT>
</text></ref><ref id="B161"><text><SENT sid="18178" pm="."><plain>151DmitrievRIKorneenkoTVBessonovAAShakhparonovMIModyanovNNPestovNBCharacterization of hampin/MSL1 as a node in the nuclear interactomeBiochemical and Biophysical Research Communications20073554105110572-s2.0-3384764534517335777 </plain></SENT>
</text></ref><ref id="B162"><text><SENT sid="18179" pm="."><plain>152MoirRDWillisIMTetratricopeptide repeats of TFC4 and a limiting step in the assembly of the initiation factor TFIIIBAdvances in Protein Chemistry200467931212-s2.0-124227388414969725 </plain></SENT>
</text></ref><ref id="B163"><text><SENT sid="18180" pm="."><plain>153CrevelGBennettDCotterillSThe human TPR protein TTC4 is a putative Hsp90 co-chaperone which interacts with CDC6 and shows alterations in transformed cellsPLoS ONE2008332-s2.0-45849099158e1737 </plain></SENT>
</text></ref><ref id="B164"><text><SENT sid="18181" pm="."><plain>154XuDZalmasLPla ThangueNBA transcription cofactor required for the heat-shock responseEMBO Reports2008976626692-s2.0-4644910766518451878 </plain></SENT>
</text></ref><ref id="B165"><text><SENT sid="18182" pm="."><plain>155XuDla ThangueNBStrap: a versatile transcription co-factorCell Cycle2008716245624572-s2.0-4974912603818719389 </plain></SENT>
</text></ref><ref id="B166"><text><SENT sid="18183" pm="."><plain>156ZhangYMurshidAPrinceTCalderwoodSKProtein kinase A regulates molecular chaperone transcription and protein aggregationPLoS ONE2011612e28950 </plain></SENT>
</text></ref><ref id="B167"><text><SENT sid="18184" pm="."><plain>157DaviesLParaskevopoulouESadeqMRegulation of glucocorticoid receptor activity by a stress responsive transcriptional cofactorMolecular Endocrinology201125158712-s2.0-7865089718021147850 </plain></SENT>
</text></ref><ref id="B168"><text><SENT sid="18185" pm="."><plain>158KuzhandaiveluNCongYSInouyeCYangWMSetoEXAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivationNucleic Acids Research19962423474147502-s2.0-00298035508972861 </plain></SENT>
</text></ref><ref id="B169"><text><SENT sid="18186" pm="."><plain>159CaiWKramarovaTVBergPKorbonitsMPongratzIThe immunophilin-like protein XAP2 is a negative regulator of estrogen signaling through interaction with estrogen receptor α PLoS ONE2011610e25201 </plain></SENT>
</text></ref><ref id="B170"><text><SENT sid="18187" pm="."><plain>160YinZHenryECGasiewiczTA(-)-epigallocatechin-3-gallate is a novel Hsp90 inhibitorBiochemistry20094823363452-s2.0-5984911285019113837 </plain></SENT>
</text></ref><ref id="B171"><text><SENT sid="18188" pm="."><plain>161MazumdarAWangRAMishraSKTranscriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressorNature Cell Biology20013130372-s2.0-003514644211146623 </plain></SENT>
</text></ref><ref id="B144"><text><SENT sid="18189" pm="."><plain>162RomanoPHeZLuanSIntroducing immunophilins. From organ transplantation to plant biologyPlant Physiology20041344124112432-s2.0-194250217115084722 </plain></SENT>
</text></ref><ref id="B145"><text><SENT sid="18191" pm="."><plain>163DuinaAAChangHCJMarshJALindquistSGaberRFA cyclophilin function in Hsp90-dependent signal transductionScience19962745293171317152-s2.0-00298075308939862 </plain></SENT>
</text></ref><ref id="B146"><text><SENT sid="18192" pm="."><plain>164PeriyasamySWarrierMTillekeratneMPMShouWSanchezERThe immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanismsEndocrinology200714810471647262-s2.0-3474891568517615153 </plain></SENT>
</text></ref><ref id="B147"><text><SENT sid="18193" pm="."><plain>165PeriyasamySHindsTJr.ShemshediniLShouWSanchezERFKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin AOncogene20102911169117012-s2.0-7794965480120023700 </plain></SENT>
</text></ref><ref id="B148"><text><SENT sid="18194" pm="."><plain>166KumarPMarkPJWardBKMinchinRFRatajczakTEstradiol-regulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cellsBiochemical and Biophysical Research Communications200128412192252-s2.0-003480994211374893 </plain></SENT>
</text></ref><ref id="B152"><text><SENT sid="18195" pm="."><plain>167WochnikGMRüeggJAbelGASchmidtUHolsboerFReinTFK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cellsThe Journal of Biological Chemistry20052806460946162-s2.0-1424426226115591061 </plain></SENT>
</text></ref><ref id="B153"><text><SENT sid="18196" pm="."><plain>168McKeenHDMcAlpineKValentineAA novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signalingEndocrinology200814911572457342-s2.0-5434908478818669603 </plain></SENT>
</text></ref><ref id="B154"><text><SENT sid="18197" pm="."><plain>169McKeenHDByrneCJitheshPVFKBPL regulates estrogen receptor signaling and determines response to endocrine therapyCancer Research2010703109011002-s2.0-7624909898120103631 </plain></SENT>
</text></ref><ref id="B156"><text><SENT sid="18198" pm="."><plain>170VelascoAMGillisKALiYIdentification and validation of novel androgen-regulated genes in prostate cancerEndocrinology20041458391339242-s2.0-384309160615131019 </plain></SENT>
</text></ref><ref id="B157"><text><SENT sid="18199" pm="."><plain>171NiLYangCSGioeliDFriersonHToftDOPaschalBMFKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cellsMolecular and Cellular Biology2010305124312532-s2.0-7674910810720048054 </plain></SENT>
</text></ref><ref id="B172"><text><SENT sid="18200" pm="."><plain>172HanahanDWeinbergRAThe hallmarks of cancerCell2000100157702-s2.0-003461463710647931 </plain></SENT>
</text></ref><ref id="B173"><text><SENT sid="18201" pm="."><plain>173HanahanDWeinbergRAHallmarks of cancer: the next generationCell201114456466742-s2.0-7995228412721376230 </plain></SENT>
</text></ref><ref id="B174"><text><SENT sid="18202" pm="."><plain>174NeckersLWorkmanPHsp90 molecular chaperone inhibitors: are we there yet?Clinical Cancer Research201218647622215907 </plain></SENT>
</text></ref><ref id="B175"><text><SENT sid="18203" pm="."><plain>175WhitesellLMimnaughEGde CostaBMyersCENeckersLMInhibition of heat shock protein HSP90-pp60(v-src) heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformationProceedings of the National Academy of Sciences of the United States of America19949118832483282-s2.0-00280649408078881 </plain></SENT>
</text></ref><ref id="B176"><text><SENT sid="18204" pm="."><plain>176ModiSStopeckALindenHHSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabClinical Cancer Research20111715513251392-s2.0-7996098535421558407 </plain></SENT>
</text></ref><ref id="B177"><text><SENT sid="18205" pm="."><plain>177ModiSStopeckATGordonMSCombination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: a phase I dose-escalation studyJournal of Clinical Oncology20072534541054172-s2.0-3684905500718048823 </plain></SENT>
</text></ref><ref id="B178"><text><SENT sid="18206" pm="."><plain>178RohdeMDaugaardMJensenMHHelinKNylandstedJJäätteläMMembers of the heat-shock protein 70 family promote cancer cell growth by distinct mechanismsGenes and Development20051955705822-s2.0-1464443581915741319 </plain></SENT>
</text></ref><ref id="B179"><text><SENT sid="18207" pm="."><plain>179WadhwaRTairaKKaulSCAn Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where?Cell Stress and Chaperones20027330931612482206 </plain></SENT>
</text></ref><ref id="B180"><text><SENT sid="18208" pm="."><plain>180PowersMVClarkePAWorkmanPDual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosisCancer Cell20081432502622-s2.0-5034909680318772114 </plain></SENT>
</text></ref><ref id="B181"><text><SENT sid="18209" pm="."><plain>181PowersMVJonesKBarillariCWestwoodIvan MontfortRLMWorkmanPTargeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?Cell Cycle201098154215502-s2.0-7795357683820372081 </plain></SENT>
</text></ref><ref id="B182"><text><SENT sid="18210" pm="."><plain>182HieronymusHLambJRossKNGene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulatorsCancer Cell20061043213302-s2.0-3374943391617010675 </plain></SENT>
</text></ref><ref id="B183"><text><SENT sid="18211" pm="."><plain>183ZhangTHamzaACaoXA novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cellsMolecular Cancer Therapeutics2008711621702-s2.0-3834915357218202019 </plain></SENT>
</text></ref><ref id="B184"><text><SENT sid="18212" pm="."><plain>184SalminenALehtonenMPaimelaTKaarnirantaKCelastrol: molecular targets of Thunder God VineBiochemical and Biophysical Research Communications201039434394422-s2.0-7795051690820226165 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="18213" pm="."><plain>Reaction cycle for Hsp70 family polypeptides. Hsp70 proteins are portrayed as consisting of two major functional domains, including an N-terminal ATPase domain and a C-terminal client protein binding domain. When ATP occupies the ATPase domain, the C-terminal client protein-binding domain has weak affinity for clients. In the first step in chaperoning, the client protein (here depicted as unfolded) associated with a J domain protein (JDP) is able to bind Hsp70. </plain></SENT>
<SENT sid="18217" pm="."><plain>This interaction causes allosteric changes in the N-terminal ATPase domain, ATP hydrolysis, and tight binding of substrate. Release of the client is then associated with nucleotide exchange loss of ADP and phosphate and replacement with ATP. In order to occur at a significant rate in cells nucleotide exchange factors such as Bag1 and HspBP1 are required. Released client is depicted as “folded.” However, the precise nature of the processes involved in achieving this state are not clear. We also show an alternative fate for Hsp70 client complexes involving the scaffold protein Hop. Hop can bind the extreme C-terminus of Hsp70 and couple it to other proteins such as Hsp90. </plain></SENT>
<SENT sid="18223" pm="."><plain>Clients can thus be passed from Hsp70 to Hsp90 in a coordinated folding process. </caption><graphic xlink:href="SCIENTIFICA2013-217513.001"/></fig></SecTag><SecTag type="FIG"><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="18224" pm="."><plain>Reaction Cycle for Hsp90. </plain></SENT>
<SENT sid="18225" pm="."><plain>Hsp90 functions as a dimer in a cycle of client binding, ATP binding, ATPase activity, and nucleotide exchange as with Hsp70. </plain></SENT>
<SENT sid="18226" pm="."><plain>The dimers are in an open conformation when empty and a more closed conformation when ATP binds. Substrate binding is assisted by co-chaperone Sgt1. </plain></SENT>
<SENT sid="18228" pm="."><plain>For Hsp90, in which prolonged “holding” of clients seems an important component of its cellular function, the co-chaperones p23 and Cdc37 inhibit ATPase activity and stabilize Hsp90 client complexes. For nucleotide exchange to take place after ATPase activity eventually occurs, Aha1 functions as an exchange factor. As with Hsp70, triage of the protein between pathways of protein quality control involves scaffold protein Hop that binds the C-terminal TPR domain-binding motif (TBD). </plain></SENT>
<SENT sid="18231" pm="."><plain>Through the TBP, Hsp90 can interact with a range of TPR domain containing co-chaperones that regulate intracellular function. </caption><graphic xlink:href="SCIENTIFICA2013-217513.002"/></fig></SecTag><SecTag type="FIG"><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="18232" pm="."><plain>Oncogenic or tumor suppressive influence of molecular co-chaperones. (Hop is shown twice in the cartoon to depict its role in bridging Hsp70 and Hsp90 as well as its pro-oncogenic influence). </caption><graphic xlink:href="SCIENTIFICA2013-217513.003"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="18234" pm="."><plain>Cochaperones. </caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="18235" pm="."><plain>Name </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="18236" pm="."><plain>Function </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="18237" pm="."><plain>Conserved domain </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="18238" pm="."><plain>Role in cancer </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="18239" pm="."><plain>Associated proteins </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="18240" pm="."><plain>Reference </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="6" align="center" rowspan="1"><text><SENT sid="18241" pm="."><plain>Hsp70 </plain></SENT>
</text></td></tr><tr><td align="left" colspan="6" rowspan="1"><text><SENT sid="18242" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18243" pm="."><plain>JDP </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18244" pm="."><plain>Substrate selection </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18245" pm="."><plain>J </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18246" pm="."><plain>Supp </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18247" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18248" pm="."><plain>[101–105] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18249" pm="."><plain>HspBP1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18250" pm="."><plain>Nucleotide exchange </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18251" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18252" pm="."><plain>Supp </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18253" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18254" pm="."><plain>[96–99] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18255" pm="."><plain>Bag1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18256" pm="."><plain>Nucleotide exchange </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18257" pm="."><plain>BAG, UBL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18258" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18259" pm="."><plain>  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18260" pm="."><plain>[92] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18261" pm="."><plain>Bag3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18262" pm="."><plain>Nucleotide exchange </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18263" pm="."><plain>BAG, WW </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18264" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18265" pm="."><plain>HspB8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18266" pm="."><plain>[90, 91, 93] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18267" pm="."><plain>Hop </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18268" pm="."><plain>Adaptor </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18269" pm="."><plain>TPR </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18270" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18271" pm="."><plain>TDB proteins </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18272" pm="."><plain>[107–109] </plain></SENT>
</text></td></tr><tr><td align="left" colspan="6" rowspan="1"><text><SENT sid="18273" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td colspan="6" align="center" rowspan="1"><text><SENT sid="18274" pm="."><plain>Hsp90 </plain></SENT>
</text></td></tr><tr><td align="left" colspan="6" rowspan="1"><text><SENT sid="18275" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18276" pm="."><plain>Sgt1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18277" pm="."><plain>Substrate selection </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18278" pm="."><plain>CHORD </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18279" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18280" pm="."><plain>Hsp70 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18281" pm="."><plain>[116–119] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18282" pm="."><plain>P23 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18283" pm="."><plain>ATPase inhibitor </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18284" pm="."><plain>p23 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18285" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18286" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18287" pm="."><plain>[112–115] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18288" pm="."><plain>Aha1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18289" pm="."><plain>ATPase inhibitor </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18290" pm="."><plain>Aha1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18291" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18292" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18293" pm="."><plain>[131, 132] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18294" pm="."><plain>Cdc37 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18295" pm="."><plain>ATPase inhibitor </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18296" pm="."><plain>Hsp90 bd </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18297" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18298" pm="."><plain>Kinases </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18299" pm="."><plain>[120–129] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18300" pm="."><plain>Hop </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18301" pm="."><plain>Adaptor </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18302" pm="."><plain>TPR </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18303" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18304" pm="."><plain>TDB </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18305" pm="."><plain>[107–109] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18306" pm="."><plain>Cyp40 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18307" pm="."><plain>Immunophilin </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18308" pm="."><plain>TPR, PPiase </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18309" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18310" pm="."><plain>TDB </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18311" pm="."><plain>[32, 134] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18312" pm="."><plain>FKBP1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18313" pm="."><plain>Immunophilin </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18314" pm="."><plain>TPR, PPiase </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18315" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18316" pm="."><plain>TDB </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18317" pm="."><plain>[135, 136] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18318" pm="."><plain>FKBP2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18319" pm="."><plain>Immunophilin </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18320" pm="."><plain>TPR, PPiase </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18321" pm="."><plain>Onc </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18322" pm="."><plain>TDB, dynein </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18323" pm="."><plain>[134, 137, 138] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18324" pm="."><plain>PP5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18325" pm="."><plain>Protein phosphatase </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18326" pm="."><plain>TPR </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18327" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18328" pm="."><plain>TDB </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18329" pm="."><plain>[139–147] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18330" pm="."><plain>TTC4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18331" pm="."><plain>Adaptor, replication </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18332" pm="."><plain>TPR </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18333" pm="."><plain>Supp </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18334" pm="."><plain>TDB, Myst, MOF </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18335" pm="."><plain>[148–153] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18336" pm="."><plain>TTC5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18337" pm="."><plain>Adaptor, transcription </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18338" pm="."><plain>TPR </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18339" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18340" pm="."><plain>TDB, p300 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18341" pm="."><plain>[88, 154–157] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="18342" pm="."><plain>XAP2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18343" pm="."><plain>Nuclear receptors </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18344" pm="."><plain>TPR </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18345" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18346" pm="."><plain>TDB </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="18347" pm="."><plain>[158–161] </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></floats-group></article>
